Publications by authors named "Alison Forgie"

Claim this Profile
E
Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study.
Tae Min Kim, Nehal J Lakhani, Jacob Soumerai, Manali Kamdar, Justin F Gainor, Alison Forgie

Haematologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Omid Hamid, Alberto A Chiappori, John A Thompson, Toshihiko Doi, Siwen Hu-Lieskovan, Alison Forgie

J Immunother Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.
James J Harding, Ignacio Garrido-Laguna, Xiaoying Chen, Cynthia Basu, Afshin Dowlati, Alison Forgie

Front Immunol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.
Siwen Hu-Lieskovan, Fadi Braiteh, Juneko E Grilley-Olson, Xiao Wang, Alison Forgie

Target Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
Melissa L Johnson, Fadi Braiteh, Juneko E Grilley-Olson, Jeffrey Chou, Jasmine Davda, Alison Forgie

JAMA Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial.
Barry Gumbiner, Brooke Esteves, Vanessa Dell, Tenshang Joh, Pamela D Garzone, Alison Forgie

Endocrine· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of a high-fidelity antibody against nerve growth factor using library scanning mutagenesis and validation with structures of the initial and optimized Fab-antigen complexes.
Sherry L La Porte, Charles Eigenbrot, Mark Ultsch, Wei-Hsien Ho, Davide Foletti, Alison Forgie

MAbs· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TrkB and TrkC agonist antibodies improve function, electrophysiologic and pathologic features in Trembler J mice.
Zarife Sahenk, Gloria Galloway, Chris Edwards, Vinod Malik, Brian K Kaspar, Alison Forgie

Exp Neurol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proneurotrophins require endocytosis and intracellular proteolysis to induce TrkA activation.
Jacqueline Boutilier, Claire Ceni, Promila C Pagdala, Alison Forgie, Kenneth E Neet

J Biol Chem· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Appetite enhancement and weight gain by peripheral administration of TrkB agonists in non-human primates.
John C Lin, David Tsao, Paul Barras, Raul A Bastarrachea, Bob Boyd, Alison Forgie

PLoS One· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with trkC agonist antibodies delays disease progression in neuromuscular degeneration (nmd) mice.
Rocio Ruiz, John Lin, Alison Forgie, Davide Foletti, David Shelton

Hum Mol Genet· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macrophage stimulating protein is a target-derived neurotrophic factor for developing sensory and sympathetic neurons.
Alison Forgie, Sean Wyatt, Pamela H Correll, Alun M Davies

Development· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis